As Sky News research revealed thousands of severely obese patients are facing severely delayed treatment, here we look at the ...

A post hoc analysis of the SUMMIT trial, published in JACC, reveals that baseline body mass index (BMI) and fat distribution ...

The updated standard replaces three previous guidelines and reflects the latest thinking on tackling obesity through the ...

Eli Lilly and Novo Nordisk are actively exploring other medical uses for their GLP-1 drugs, and have already seen some ...

Novo Nordisk remains a strong buy despite share price dip, thanks to its robust drug pipeline, massive market potential, and ...

Hims & Hers delivered strong Q2 growth, driven by compounded GLP-1 offerings, but faces uncertainty as regulatory and supply ...

People using weight loss medication have been told it's not a "quick fix" with many at risk of regaining their lost weight.

Digital health company Noom has started offering lower doses of GLP-1 agonist semaglutide, the active ingredient in Novo Nordisk's weight-loss drug Wegovy, at a knock-down price. The 'microdose' ...

Patients ending obesity medication or finishing a weight management programme should be offered support to help keep the ...

People using weight loss medication have been warned it is not a "quick fix" with many at risk of regaining their lost weight ...

Thousands of patients desperate to access the “King Kong” of weight loss jabs are facing a postcode lottery, research reveals ...

Facebook posts reveal more GI side effects from semaglutide drugs like Ozempic than Mounjaro, offering new insights into ...